Inovio reports fourth quarter and full year 2022 financial results and clinical highlights

Announces topline results from reveal2, the second phase 3 trial evaluating vgx-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (hsil) trial results did not meet the primary endpoint in the biomarker-selected population trial results did achieve statistical significance in the all-participants population highlights progress of promising product candidates: positive preliminary data from phase 1/2 trial of ino-3107 for the treatment of recurrent respiratory papillomatosis positive phase 1b data for ino-4201 as ebola booster for ervebo® as primary series positive data from a phase 1/2 trial with ino-5401 in patients with glioblastoma updated results published for ino-3112, a product candidate being evaluated for the treatment of hpv-related cancers ended 2022 with $253 million in cash, cash equivalents, and short-term investments and maintains cash runway projections to first quarter 2025 management will host conference call today at 4:30 p.m. et plymouth meeting, pa.
INO Ratings Summary
INO Quant Ranking